ニコチン作動薬
参考資料

↑  Henningfield, Jack E; Zeller, Mitch (2006), “Nicotine psychopharmacology research contributions to United States and global tobacco regulation: a look back and a look forward”, Psychopharmacology 184 (3–4):  286–291, doi:10.1007/s00213-006-0308-4, PMID 16463054
1 2  Haroutunian, Vahram; Barnes, Edward; Davis, KL (1985), “Cholinergie modulation of memory in rats”, Psychopharmacology 87 (3):  266–271, doi:10.1007/BF00432705, PMID 3001803
1 2 3 4 5  Buccafusco, J. J. (2004), “Neuronal nicotinic receptor subtypes: defining therapeutic targets”, Molecular Interventions 4 (5):  285–295, doi:10.1124/mi.4.5.8, PMID 15471911, http://molinterv.aspetjournals.org/cgi/reprint/4/5/285.pdf
↑  Buccafusco, J. J.; Jackson, W. J.; Terry Jr, AV; Marsh, KC; Decker, MW; Arneric, SP (1995), “Improvement in performance of a delayed matching-to-sample task by monkeys following ABT-418: a novel cholinergic channel activator for memory enhancement”, Psychopharmacology 120 (3):  256–266, doi:10.1007/BF02311172, PMID 8524972
↑  Ludwig, J.; Höffle-Maas, A. (2010), “Localization by site-directed mutagenesis of a galantamine binding site on α7 nicotinic acetylcholine receptor extracellular domain”, Journal of Receptors and Signal Transduction 30 (6):  469–483, doi:10.3109/10799893.2010.505239, PMID 21062106
↑  Liu, Zhaoping; Zhang, J; Berg, Darwin K. (2007), “Role of endogenous nicotinic signaling in guiding neuronal development”, Biochemical Pharmacology 74 (8):  1112–1119, doi:10.1016/j.bcp.2007.05.022, PMC 2116993, PMID 17603025, http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=2116993
1 2  Gotti, C.; Clementi, F. (2004), “Neuronal nicotinic receptors: from structure to pathology”, Progress in Neurobiology 74 (6):  363–396, doi:10.1016/j.pneurobio.2004.09.006, PMID 15649582
1 2 3  Paterson, David; Nordberg, Agneta (2000), “Neuronal nicotinic receptors in the human brain”, Progress in Neurobiology 61 (1):  75–111, doi:10.1016/s0301-0082(99)00045-3, PMID 10759066
↑  Sala, F.; Nistri, A.; Criado, M. (2008), “Nicotinic acetylcholine receptors of adrenal chromaffin cells”, Acta Physiologica 192 (2):  203–212, doi:10.1111/j.1748-1716.2007.01804.x, PMID 18005395, http://www3.interscience.wiley.com/cgi-bin/fulltext/119423079/PDFSTART [リンク切れ]
1 2 3  Itier, Valérie; Bertrand, Daniel (2001), “Neuronal nicotinic receptors: from protein structure to function”, FEBS Letters 504 (3):  118–125, doi:10.1016/S0014-5793(01)02702-8, PMID 11532443
1 2  Lindstrom, JM (2003), “Nicotinic acetylcholine receptors of muscles and nerves”, Annals of the New York Academy of Sciences 998:  41–52, doi:10.1196/annals.1254.007, PMID 14592862, http://www3.interscience.wiley.com/cgi-bin/fulltext/120779503/PDFSTART [リンク切れ]
↑  Mihailescu, Stefan; Drucker-Colín, René (2000), “Nicotine, Brain Nicotinic Receptors, and Neuropsychiatric Disorders”, Archives of Medical Research 31 (2):  131–144, doi:10.1016/S0188-4409(99)00087-9, PMID 10880717
↑  Arias, Hugo R. (1997), “Topology of ligand binding sites on the nicotinic acetylcholine receptor”, Brain Research Reviews 25 (2):  133–191, doi:10.1016/S0165-0173(97)00020-9, PMID 9403137
1 2 3 4  Haydar, Simon N.; Ghiron, Chiara; Bettinetti, Laura; Bothman, Hendrick; Comery, Thomas A.; Dunlop, John; La Rosa, Salvatore; Micco, Iolanda et al. (2009), “SAR and biological evaluation of SEN12333/WAY-317538: Novel alpha 7 nicotinic acetylcholine receptor agonist”, Bioorganic & Medicinal Chemistry 17 (14):  5247–5258, doi:10.1016/j.bmc.2009.05.040, PMID 19515567
↑  Brunton, Laurence L.; Lazo, John S.; Parker, Keith L., eds. (2006), Goodman & Gilman's The Pharmacological Basis of Therapeutics (11 ed.), McGRAW HILL, ISBN 978-0-07-142280-2
↑  “The comparative pharmacology and up-regulation of rat neuronal nicotinic receptor subtype binding sites stably expressed in transfected mammalian cells”. The Journal of Pharmacology and Experimental Therapeutics 310 (1):  98–107. (July 2004). doi:10.1124/jpet.104.066787. PMID 15016836.
↑  Unwin, Nigel (2004), “Refined Structure of the Nicotinic Acetylcholine Receptor at 4 A° Resolution”, Journal of Molecular Biology 346 (4):  967–989, doi:10.1016/j.jmb.2004.12.031, PMID 15701510
↑  Cassels, Bruce K.; Bermúdez, Isabel; Dajas, Federico; Abin-Carriquiry, J. Andrés; Wonnacott, Susan (2005), “From ligand design to therapeutic efficacy: the challenge for nicotinic receptor research”, Drug Discovery Today 10 (23–24):  1657–1665, doi:10.1016/S1359-6446(05)03665-2, hdl:10533/176659, PMID 16376826
↑  Gotti, C.; Fornasari, D.; Clementi, F. (1997), “Human Neuronal Nicotinc Receptors”, Progress in Neurobiology 53 (2):  199–237, doi:10.1016/S0301-0082(97)00034-8, PMID 9364611
↑  Tøndera, Janne E.; Olesena, Preben H.; Hansena, John Bondo; Begtrupb, Mikael; Petterssona, Ingrid (2001), “An improved nicotinic pharmacophore and a stereoselective CoMFA-model for nicotinic agonists acting at the central nicotinic acetylcholine receptors labelled by [3H]-N-methylcarbamylcholine”, Journal of Computer-Aided Molecular Design 15 (3):  247–258, Bibcode: 2001JCAMD..15..247T, doi:10.1023/A:1008140021426, PMID 11289078
↑  Cooper, Julia C.; Gutbrod, Oliver; Witzemann, Veit; Methfessel, Christoph (1996), “Pharmacology of the nicotinic acetylcholine receptor from fetal rat muscle expressed in Xenopus oocytes”, European Journal of Pharmacology 309 (3):  287–298, doi:10.1016/0014-2999(96)00294-4, PMID 8874153
↑  Carter, Chris R.J.; Cao, Liren; Kawai, Hideki; Smith, Peter A.; Dryden, William F.; Raftery, Michael A.; Dunn, Susan M.J. (2007), “Chain length dependence of the interactions of bisquaternary ligands with the Torpedo nicotinic acetylcholine receptor”, Biochemical Pharmacology 73 (3):  417–426, doi:10.1016/j.bcp.2006.10.011, PMID 17118342
↑  Charton, Yves; Guillonneau, Claude.; Lockhart, Brian; Lestageb, Pierre; Goldsteina, Solo (2008), “Preparation and affinity profile of novel nicotinic ligands”, Bioorganic & Medicinal Chemistry Letters 18 (6):  2188–2193, doi:10.1016/j.bmcl.2007.12.075, PMID 18262785
↑  Walker, Daniel P.; Wishka, Donn G.; Piotrowski, David W.; Jia, Shaojuan; Reitz, Steven C.; Yates, Karen M.; Myers, Jason K.; Vetman, Tatiana N. et al. (2006), “Design, synthesis, structure–activity relationship, and in vivo activity of azabicyclic aryl amides as a7 nicotinic acetylcholine receptor agonists”, Bioorganic & Medicinal Chemistry 14 (24):  8219–8248, doi:10.1016/j.bmc.2006.09.019, PMID 17011782
↑  http://www.envivopharma.com - Nicotinic Alpha7 Acetylcholine Receptor Agonist Program Archived 2010-01-07 at the Wayback Machine.
↑  Rollema, H.; Chambers, L.K; Coe, J.W.; Glowa, J.; Hurst, R.S.; Lebel, L.A; Lu, Y.; Mansbach, R.S. et al. (2007), “Pharmacological profile of the α4β2 nicotinic acetylcholine receptor partial agonist varenicline, an effective smoking cessation aid”, Neuropharmacology 52 (3):  985–994, doi:10.1016/j.neuropharm.2006.10.016, PMID 17157884
1 2  “CHAMPIX 0.5 mg film-coated tablets - Summary of Product Characteristics (SmPC) - (eMC)”. emc.medicines.org.uk. 2012年12月24日時点のオリジナルよりアーカイブ。2021年11月5日閲覧。
↑  “Reminyl XL 8mg prolonged release capsules - Summary of Product Characteristics (SmPC) - (eMC)”. emc.medicines.org.uk. 2012年12月24日時点のオリジナルよりアーカイブ。2021年11月5日閲覧。
1 2 3 4  Rang, H. P. (2003), Pharmacology, Edinburgh: Churchill Livingstone, ISBN 978-0-443-07145-4  Page 149
↑  Dani, John A.; Biasi, Mariella De (2001), “Cellular mechanisms of nicotine addiction”, Pharmacology Biochemistry and Behavior 70 (4):  439–446, doi:10.1016/S0091-3057(01)00652-9, PMID 11796143
↑  XI, Zheng-xiong; Spiller, Krista; Gardner, Eliot L. (2009), “Mechanism-based medication development for the treatment of nicotine dependence”, Acta Pharmacol Sin 30 (6):  723–739, doi:10.1038/aps.2009.46, PMC 3713229, PMID 19434058, ProQuest 213027402, http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=3713229
↑  http://www.accessdata.fda.gov/drugsatfda_docs/label/2004/16968s022lbl.pdf
↑  Tuba, Zoltan; Maho, Sandor; Vizi, E. Sylvester (2002), “Synthesis and Structure-Activity Relationships of Neuromuscular Blocking Agents”, Current Medicinal Chemistry 9 (16):  1507–1536, doi:10.2174/0929867023369466, PMID 12171561, ProQuest 215095660
↑  “Anectine Injection - Summary of Product Characteristics (SmPC) - (eMC)”. emc.medicines.org.uk. 2012年12月24日時点のオリジナルよりアーカイブ。2021年11月6日閲覧。
↑  Carroll, F. Ivy (2004), “Epibatidine structure-activity relationships”, Bioorganic & Medicinal Chemistry Letters 14 (8):  1889–1896, doi:10.1016/j.bmcl.2004.02.007, PMID 15050621
↑  Unless else specified in boxes, then reference is: Table 10-3 in: Rod Flower; Humphrey P. Rang; Maureen M. Dale; Ritter, James M. (2007). Rang & Dale's pharmacology. Edinburgh: Churchill Livingstone. ISBN 978-0-443-06911-6
↑  “Methacholine challenge testing: identifying its diagnostic role, testing, coding, and reimbursement”. Chest 131 (6):  1932–5. (June 2007). doi:10.1378/chest.06-1385. PMID 17565027. https://journal.chestnet.org/article/S0012-3692(15)37533-4/fulltext.
↑  Akk, Gustav; Auerbach, Anthony (1999-12-01). “Activation of muscle nicotinic acetylcholine receptor channels by nicotinic and muscarinic agonists”. British Journal of Pharmacology 128 (7):  1467–1476. doi:10.1038/sj.bjp.0702941. ISSN 0007-1188. PMC 1571784. PMID 10602325. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1571784/.
ABT-418の構造式
ニコチン受容体の分類
ニコチン受容体の例
ピリジン-シクロプロパン誘導体
SEN12333／WAY-317538
α7作動薬の基本構造